Biologic DMARDs (bDMARDs) confer a protective effect in patients with rheumatoid arthritis, lowering risk of developing sepsis as well as reducing mortality after serious infection and sepsis, according to results from a German registry presented at the 2015 ACR/ARHP Annual Meeting.
Adding methotrexate (MTX) to golimumab (GLM) therapy might significantly improve some symptoms among patients diagnosed with psoriatic arthritis (PsA), suggests a study reported at the 2015 ACR/ARHP Annual Meeting.
Treatment with tabalumab did not significantly affect serum creatinine, glomerular filtration rate, or urine protein/creatinine ratio over 52 weeks vs. placebo, investigators reported at the 2015 ACR/ARHP Annual Meeting.
Data presented at the 2015 ACR/ARHP Annual Meeting showed that patients with active nonradiographic axial spondyloarthritis who received golimumab showed greater improvement in quality of life and work productivity outcomes than placebo.
Patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) who develop hypersensitivity reactions to infliximab, etanercept and adalimumab are more likely to have positive skin tests despite the absence of an overall relationship with antidrug antibody (ADA) levels, according to a study reported at the 2015 ACR/ARHP Annual Meeting.
Dietary omega-3 fatty acid-rich fish consumption, but not omega-3 supplements alone, confer a protective effect against recurrent gout attacks, reported MaryAnn Zhang, MD, from the Boston University School of Medicine, Boston, MA, at the 2015 ACR/ARHP Annual Meeting.
A non-TNF-targeted biologic showed better efficacy than a second anti-TNF agent for patients with rheumatoid arthritis and insufficient response to TNF-inhibitors, according to research presented at the 2015 ACR/ARHP Annual Meeting.
Long-term administration of mavrilimumab is safe and offers sustained clinical efficacy against moderate-to-severe rheumatoid arthritis (RA), according to an open-label extension study reported at the 2015 ACR/ARHP Annual Meeting
Ustekinumab (UST) benefits patients with psoriatic arthritis (PsA) with spondylitis and peripheral joint involvement, according to an post-hoc analysis of results from the PSUMMIT 1 & 2 phase 3 double-blind, placebo-controlled clinical trials, reported at the 2015 ACR/ARHP Annual Meeting.
Longer-term efficacy and safety data from the Phase 3 PALACE 1 study have confirmed that apremilast continues to demonstrate sustained and clinically meaningful improvements in psoriatic arthritis signs and symptoms at 3 years in patients who remained on the treatment, investigators concluded at the 2015 ACR/ARHP Annual Meeting.
